According to a research report released by Citi, MEDBOT-B (02252) issued a strong positive profit alert for the 2025 fiscal year, guiding for a year-on-year revenue increase of 110% to 120%. This surpassed the bank's expectation of a 100% rise and the market consensus of a 94% increase. The bank views the revenue beat as a key highlight, confirming that the company is in a phase of rapid global business expansion, with revenue growth being the most critical metric for investors. Citi maintains a "Buy" rating on MEDBOT with a target price of HK$32. The report mentioned that this momentum is primarily driven by overseas orders for the "Tumai" robot surging to over 100 units in the 2025 fiscal year, exceeding the August guidance of 70 to 80 units, thereby providing excellent visibility for revenue conversion in the 2026 fiscal year. The market reacted positively on January 21st to the newly released national "Guidelines for Establishing Price Items for Pathology-related Medical Services (Trial)". Shares of MEDBOT and its peers rose. The bank considers this policy a milestone, as it reduces the risks associated with the commercialization path and provides a clear, unified framework for industry growth.